Groups complain that best-practice guidance appears not to have been shared among national authorities
The leaders of Europe’s medical regulators seem to have reneged on commitments around helping to ensure that the results of clinical trials are made public, various medical groups have complained.
Representatives of five medical groups wrote to the Heads of Medicines Agencies on 21 March, expressing “deep concern” that the HMA—leaders of national medical regulators in the European Economic Area—“appear to have backtracked” on commitments they made in July 2021.
This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com
Pivot-RP users can log in and view the article via this link.